Therapeutic Biologic for Treatment of Hepatocellular Carcinoma
AssigneeChina Synthetic Rubber Corporation
InventorsKuo-Jang Kao, Yun-Hsin Wang
Life of this patent
Estimating the term…
Abstract
The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
Claims20
A nucleic acid encoding a conjugate comprising a coagulating agent conjugated to an antibody that binds an extracellular domain epitope of human PLVAP.
A method of reducing volume of a tumor with PLVAP-positive vasculature, or inducing thrombosis and necrosis of a tumor with PLVAP-positive vasculature, in a mammalian subject in need thereof, comprising administering an effective amount of a conjugate comprising a coagulating agent conjugated to an antibody that binds an extracellular domain epitope of human PLVAP to the subject.
A method of treating HCC in a human subject in need thereof, comprising administering a therapeutically effective amount of a conjugate comprising a coagulating agent conjugated to an antibody that binds an extracellular domain epitope of human PLVAP to the subject, wherein the conjugate is infused directly into one or more tumor-feeding arteries.
Dependencies are inferred from the claim text.